Semax Dosing Protocol

Semax is a lab-made peptide designed to sharpen focus, protect brain cells, and support cognitive performance. It was developed in Russia in the late 1980s and has been used there as a prescription medication for over two decades. Unlike the natural brain hormone it's based on (ACTH), Semax delivers the brain-boosting benefits without raising cortisol — your body's main stress hormone. Its name comes from the Russian abbreviation for "seven amino acids" (СЕМь АминоКиСлот), reflecting its seven-amino-acid structure.

What makes Semax unusual is its staying power. The peptide itself is cleared from your blood within 3–5 minutes, but a structural tail added to the molecule (the Pro-Gly-Pro extension) keeps its effects active for 20–24 hours. This means once-daily dosing works for most protocols. The same modification also boosts BDNF and NGF — two proteins your brain uses to grow new connections, consolidate memories, and repair neurons.

Semax is approved as a prescription drug in Russia and Ukraine, where it's listed on Russia's official register of vital medications (since 2011). Russian doctors prescribe it for stroke recovery, cognitive disorders, optic nerve disease, and immune support. In the largest published stroke trial, 110 patients receiving Semax (6,000 mcg/day for two 10-day courses) showed higher BDNF levels in their blood and faster recovery on standard functional assessments. Semax is manufactured by JSC Peptogen and is available in 0.1% and 1% intranasal formulations in Russia.

This compound is not FDA-approved. All information on this page is for educational and research reference purposes only.

Semax works through several brain pathways at once — boosting growth factors that help neurons thrive, fine-tuning the brain chemicals that control focus and mood, calming inflammation, and stabilizing your body's natural pain-regulating molecules. Here's how each pathway contributes.

The table below covers two distinct Semax dosing contexts. The top section (rows labeled "SubQ") shows the community-derived nootropic protocol for subcutaneous injection at 300–800 mcg/day — this is what most research users follow. The bottom section (rows labeled "IN") shows intranasal protocols from Russian clinical practice, where doses are much higher (up to 20,000 mcg/day for severe stroke). These clinical doses are included for reference but are not typical for nootropic use.

Nasal Irritation (Intranasal Route): The most commonly reported side effect of intranasal Semax is mild nasal irritation, including dryness, burning sensation, or minor mucosal discoloration. Alternating nostrils and using saline spray may reduce irritation.

Headache: Some users report mild headaches during the first few days of Semax use, particularly at higher doses. This typically resolves with continued use or dose reduction.

Sleep Disruption: Semax promotes wakefulness and dopaminergic activity. When administered too late in the day, it may interfere with sleep onset. All doses should be administered before 2 PM.

Blood Glucose Elevation (Diabetic Patients): One review of Russian clinical data noted that approximately 7.4% of diabetic patients receiving Semax experienced increases in blood glucose levels. Monitoring is recommended in diabetic individuals.

Emotional Sensitivity / Irritability: Some users report increased emotional sensitivity or mild irritability, potentially related to Semax's dopamine and serotonin pathway effects. This is typically dose-dependent.

Injection Site Reactions (Subcutaneous Route): Mild injection-site reactions (redness, itching) may occur with subcutaneous administration. Proper site rotation and aseptic technique minimize this risk.

Discontinuation / Dependence: No dependence, tolerance, or withdrawal symptoms have been reported in published Semax studies.

Evidence quality note: Semax safety data is based primarily on Russian clinical use. As of April 2026, no Western Phase 1-3 safety program with comprehensive adverse-event reporting is available.

For a cross-class safety comparison, see the PepPal Peptide Side Effects Guide.

The table below summarizes the key published research on Semax. The top rows are human studies — including the largest stroke recovery trial with 110 patients. The bottom rows are animal studies that helped explain how Semax works at the molecular level. Because Semax was developed and studied in Russia, most of this research appears in Russian medical journals rather than the Western publications (NEJM, Lancet) that are typical for FDA-tracked compounds.

Semax has the most extensive clinical track record of any Russian-developed neuropeptide. First described in scientific literature in 1991, it achieved formal approval in Russia and was placed on the Russian List of Vital & Essential Drugs in December 2011. Clinical use in Russia spans stroke treatment, traumatic brain injury rehabilitation, cognitive disorders, optic nerve disease, and immune support. The most significant published clinical data comes from stroke rehabilitation studies involving up to 110 patients, demonstrating BDNF elevation and functional recovery. As of April 2026, no ClinicalTrials.gov-registered trials exist for Semax and no Western-standard Phase 1-3 development program has been initiated.

Semax, Selank, and Noopept are the three most widely used Russian-developed nootropic compounds, and each has a distinct strength:

Choose Semax if your primary goal is cognitive performance, focus, and neuroprotection. Semax has the strongest clinical evidence for brain-cell support and BDNF elevation — especially relevant for recovery or long-term brain health.

Choose Selank if anxiety or stress management is your main concern. Selank provides benzodiazepine-level calming effects without the sedation, dependence, or cognitive dulling that comes with conventional anti-anxiety medications.

Choose Noopept if you prefer oral dosing over injections or nasal sprays. Noopept is taken by mouth, which makes it the most convenient option — though its absorption is lower than injectable peptides.

Semax and Selank are frequently combined in the Russian Nootropic Stack for a combined focus-plus-calm effect. These compounds are not interchangeable, and dose/reconstitution requirements differ significantly.

See the Selank Protocol Page for compound-specific guides.